By helping regulate blood sugar and promoting healthier eating patterns, GLP-1s can also lead to lower blood pressure and improved cholesterol levels
Trends Pharmacol Sci (2003) 24:37783
Study selection The criteria for including studies in this meta-analysis were as follows: (1) (i) randomized controlled trials (RCTs) comparing different AOMs with placebo, including glucagon-like peptide 1 receptor agonist (GLP-1 RA), dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs, GLP-1 and glucagon receptor (GCGR) dual-agonist, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and bimagrumab
It catalyzes GPX4 degradation through ACC mediation

Food & Drug Administration (2024) One-year weight reduction with semaglutide or liraglutide in clinical practice, Diabetes and Endocrinology (2024) Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity, JAMA Internal Medicine (2024) Anti-inflammatory benefits of semaglutide: State of the art, Journal of Clinical and Translational Endocrinology (2024) Fight inflammation to help prevent heart disease, Johns Hopkins Medicine Body weight and blood pressure regulation, The American Journal of Clinical Nutrition (1996) Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes, The New England Journal of Medicine (2016) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Semaglutide, StatPearls (2024) Heart failure medications, Cleveland Clinic (2022) Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns, UChicago Medicine (2024) Efficacy and safety of GLP-1 medicines for Type 2 diabetes and obesity, Diabetes Care (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

When that evidence matures, I'll update my clinical approach accordingly